On October 9, 2026, international breast and medical oncology symposiums highlighted Trodelvy® (Sacituzumab govitecan-hziy 180 mg powder for concentrate for solution for infusion) developed by Gilead Sciences as the premier Trop-2 directed antibody-drug conjugate (ADC). Delivering proven survival benefits across metastatic triple-negative breast cancer (mTNBC) and pre-treated hormone receptor-positive / HER2-negative (HR+/HER2-) metastatic breast cancer, Trodelvy establishes a vital targeted therapeutic bridge where traditional endocrine and HER2 therapies fail.

Through Onco Medicine, certified genuine Gilead manufacturer packs of Trodelvy Sacituzumab Govitecan 180mg Injection are accessible to oncology institutions, clinical research centers, and named patients globally via GDP-certified 2°C–8°C cold-chain logistics and validated Certificate of Analysis (COA) batch release.

ADC Architecture: Trop-2 Targeting & SN-38 Cytotoxic Payload

Trodelvy incorporates advanced linker and payload engineering designed for optimized tumor payload delivery:

• Targeted Trop-2 Antibody: Humanized IgG1-kappa monoclonal antibody that binds with high affinity to trophoblast cell-surface antigen 2 (Trop-2), a transmembrane glycoprotein overexpressed on >90% of triple-negative breast tumors and various epithelial carcinomas.
• Potent Topoisomerase I Inhibitor: Conjugated with SN-38, the active metabolite of irinotecan. SN-38 is approximately 1000-fold more potent than irinotecan itself, producing lethal single- and double-strand DNA breaks during S-phase cellular replication.
• High Drug-to-Antibody Ratio (DAR 7.6:1): Carries an exceptionally high payload ratio of ~7.6 SN-38 molecules per antibody without inducing antibody aggregation or premature clearance.
• Hydrolyzable CL2A Linker & Bystander Killing: Features a pH-sensitive cleavable linker that releases SN-38 intracellularly following lysosomal degradation as well as within the acidic tumor microenvironment, eliciting a robust bystander killing effect on neighboring tumor cells.

Landmark Phase 3 Evidence: ASCENT & TROPiCS-02 Trials

Practice-changing outcomes have been demonstrated across global Phase 3 clinical programs:

• The ASCENT Trial (Metastatic TNBC): Compared to single-agent chemotherapy of physician's choice in patients with relapsed/refractory mTNBC, Trodelvy demonstrated a 57% reduction in the risk of disease progression or death (median PFS 5.6 months vs. 1.7 months) and nearly doubled median overall survival (12.1 months vs. 6.7 months).
• The TROPiCS-02 Trial (HR+/HER2- Metastatic Breast Cancer): In heavily pretreated patients who had failed prior endocrine therapy, CDK4/6 inhibitors, and multiple chemotherapy lines, Trodelvy demonstrated statistically significant, clinically meaningful overall survival and PFS improvements over standard chemotherapy.

Infusion Dosing Protocols & Toxicity Management Standards

Administration requires strict adherence to institutional safety protocols:

• Dosing Regimen: Administered as an intravenous infusion at 10 mg/kg on Days 1 and 8 of continuous 21-day cycles. Treatment continues until disease progression or unacceptable toxicity.
• Premedication Regimen: Prior to each infusion, premedication with antipyretics (acetaminophen), H1 and H2 blockers, and multi-agent antiemetics (dexamethasone plus 5-HT3 receptor antagonists) is mandatory to prevent infusion reactions and chemotherapy-induced nausea.
• Neutropenia & G-CSF Support: Severe or febrile neutropenia can occur. Complete blood counts must be evaluated prior to each cycle and on Day 8. Prophylactic granulocyte colony-stimulating factors (G-CSF) are recommended for patients who develop severe neutropenia.
• Severe Diarrhea Management: Early-onset diarrhea (cholinergic) is treated with atropine; late-onset diarrhea is treated proactively with oral loperamide and aggressive electrolyte hydration.

Global Cold-Chain Sourcing via Onco Medicine

Onco Medicine facilitates rapid, legally compliant cross-border procurement of genuine Gilead Trodelvy 180mg:

• Compliant Regulatory Channels: Sourced under US FDA Personal Importation Policy (PIP), UK MHRA Named-Patient Import, Australian TGA Special Access Scheme (SAS), Brazilian ANVISA RDC import exemptions, and Middle East MOHAP authorizations.
• Uncompromising Cold-Chain (2°C–8°C): Shipped in validated thermal packaging with continuous digital temperature data loggers to guarantee biological stability from dispatch to clinic receipt within 4 to 8 business days worldwide.
• Full Batch Authentication: Supplied in original tamper-evident cartons accompanied by official batch release certificates and cold-chain compliance reports.

Contact our precision oncology desk for institutional procurement, batch availability, and express international shipping options: support@onco-medicine.com or connect directly with our oncology pharmacists via WhatsApp (+91 94275 19809).